| Cipher: |
2601 |
| Nomenclature: |
Personal medicine - predictive medicine and pharmacogenetics |
| Study programme: |
Molecular biosciences |
| Module: |
Biomedicine |
| Case holder: |
the prof.dr.sc. Sanja Kapitanović, ZN. Advisor-permanent choice
|
| Institution of the case holder: |
Ruđer Boskovic Institute
|
| Contributors - Contractors: |
the doc.dr.sc. Tamara Čačev, senior zn. Associate
the doc.dr.sc. Tanja Matijević Glavan, higher zn. Associate
|
| Subject status: |
Electoral College |
| The year in which the case is submitted: |
Year I |
| The semester in which the case is submitted: |
Semester II |
| Subject objective: |
To know the latest developments of molecular medicine related to personal medicine, i.e. medicine aimed at the individual, with the aim of presymptomatic diagnosis of hereditary diseases, predicting the course of the disease and responding to therapy in an individual
|
| Case contents: |
Introduction to basic concepts related to personal medicine (predictive and preventive medicine, pharmacogenetics and pharmacogenomics).
Genome variability, the importance of SNP polymorphisms.
Modern molecular biology techniques that allow us to analyze SNP polymorphisms.
Predictive medicine in oncology, preymptomatic molecular diagnostics of hereditary tumors and prediction of the course of the disease.
The role of SNP polymorphisms of the cytokine gene in neoangiogenesis and metastasizing.
Specifics of personal medicine in pediatrics.
Pharmacogenetics, the role of SNP polymorphisms of genes responsible for drug metabolism (TPMT, TS, MTHFR, etc.) (effectiveness of therapy, toxicity or resistance to therapy).
Pharmacogenomics, new drug creation, contolized pharmacogenetic trials.
|
| Learning outcomes: competences, knowledge, skills that the subject develops: |
1. Explain the concept of personalized medicine.
2. Anticipate the possibilities of personalized medicine and molecular diagnostics in the prevention and diagnosis of diseases in man.
3. Assess the possibilities of personalized medicine and molecular diagnostics in the process of treatment and monitoring of the course of the disease.
4. Distinguish between the molecular bases of the most common hereditary diseases in man and the possibilities of their molecular diagnostics.
5. Apply the results of scientific research on concrete examples from practice.
|
| ECTS Credits |
4 |
| Lectures |
5 |
| Seminars (IS) |
5 |
| Exercises (E) |
10 |
| Altogether |
20 |
| The way of teaching and acquiring knowledge: |
|
| Ways of teaching and acquiring knowledge: (notes) |
|
| Monitoring and evaluating students (mark in fat printing only relevant categories) |
Attendance |
| Rating method: |
Written exam, Analysis of published publication |
| Mandatory literature: |
1. Fierz W. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? Med Sci Monit 10:111-123, 2004.
2. Cancer Pharmacogenomics: SNPs, chips, and the individual patient. Cancer Invest 21:630-640, 2003.
3. Imyanitov EN et al. Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Letters 204:3-14, 2004.
4. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Letters 208:1-33, 2004.
5. Bian XW et al. Angiogenesis as an immunopharmacologic target in inflammation and cancer. Int Immunopathol 4:1537-1547, 2004.
6. Yamayoshi Y et al. Cancer pharmacogenomics: international trends. Int J Clin Oncol 10:5-13, 2005.
7. Leeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics 4:331-341, 2003.
8. Sartor RB. Clinical applications of advances in the genetics of IBD. Rev Gastroenterol Disord 3:S9, 2003.
9. Johnson JA and Evans WE. Molecular diagnostics as a predicitve tool: genetics of drug efficacy and toxicity. TRENDS in Molecular Medicine 8:300-305, 2002.
10. Roses AD. Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev/Drug Discovery 1:541-549, 2002.
11. Nebert DW and Vesell ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacology 500:267-280, 2004.
12. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett 340(2):284-95, 2013.
13. Tang B, Hsu PY, Huang TH, Jin VX. Cancer omics: from regulatory networks to clinical outcomes. Cancer Lett 340(2):277-83, 2013.
14. Khodakov D, Wang C, Zhang DY. Diagnostic based on nucleic acid sequence variant profiling: PCR, hybridization , and NGS approaches. Adv Drug Deliv Rev 2016, doi: 10.1016/j.addr.2016.04.005.
15. Schmidt KT, Chau CH, Price DK, Figg WD. Precision oncology medicine: the clinical relevance of patient specific biomarkers used to optimize cancer treatment. J Clin Pharmacol 2016, doi: 10.1002/jcph.765.
|
| Supplementary (recommended) literature: |
1. Gurwitz D, Weizman A, Rehavi M. Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. TREND in Pharmacological Sciences 24(3):123-125, 2003.
2. Frueh FW i Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 5:571-579, 2004.
|
| How to monitor the quality and performance performance (evaluation): |
Questionnaire for examining the attitudes of program users towards the program and teachers (content of the program, presentation mode, teaching material). The success of the course will be evaluated annually by the joint expert committee of the Rudjer Boskovic Institute, the University of Dubrovnik and the University of Osijek.
|
